Avni Finn, MD
Ophthalmology · Nashville, TNNPI 1184987315
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $42,966 of the $57,467 with a category attached, or 74.8%. 13 manufacturers reported payments, led by Genentech USA, Inc. at 41.0% of the total. 2025 is the largest year on record at $16,919, 4.0 times the $4,200 reported in 2019. Among ophthalmology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 88 payments — averaging $653.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$24K
- Bausch & Lomb Americas Inc.$15K
- Genentech, Inc.$9K
- AbbVie$6K
- Apellis Pharmaceuticals, Inc.$3K
- Eyepoint US, Inc.$1K
- plus $286 from 7 others
Across 13 payments — averaging $1500.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$11K
- AbbVie$8K
What the payments were for
- Consulting fees$42,96675%
- Travel & lodging$11,69820%
- Food & beverage$2,8025%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 27 | $23,587 |
| Bausch & Lomb Americas Inc. | 16 | $15,037 |
| Genentech, Inc. | 11 | $8,753 |
| AbbVie | 14 | $5,930 |
| Apellis Pharmaceuticals, Inc. | 5 | $2,872 |
| Eyepoint US, Inc. | 3 | $1,001 |
| Alimera Sciences, Inc. | 3 | $67 |
| Regeneron Healthcare Solutions, Inc. | 3 | $65 |
| Regeneron | 2 | $49 |
| Neurotech Pharmaceuticals, Inc. | 1 | $49 |
| Biogen | 1 | $24 |
| Astellas Pharma US Inc | 1 | $18 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$18,334
- Lucentis$13,645
- STELLARIS$11,056
- SURGICAL MISC$11,056
- SUSVIMO$4,500
- YUTIQ$946
- OZURDEX$723
- Non-Covered Product$150
How this compares
$57,467 in reported general payments places this provider in the 95th percentile of 323 ophthalmology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketorolac Tromethamine | 57 | $2,104 |
| Prednisolone Acetate | 68 | $2,010 |
| Brimonidine Tartrate | 29 | $812 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 37 | $562 |
| Timolol Maleate | 12 | $75 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Nashville
- Deborah ShermanNashville$3M
- Brian BiesmanNashville$630K
- Edward ChaumNashville$158K
- Jeffrey HornNashville$106K
- Louise MawnNashville$56K
- Jeffrey KammerNashville$30K
- Gary JerkinsNashville$15K
- Allison SmithNashville$13K
- Christine ShiehNashville$10K
- Ira ShivitzNashville$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.